BIO vs TEVA vs TMO Stock Comparison

Bio-Rad Laboratories, Teva Pharmaceutical Industries and Thermo Fisher Scientific Prices as of Nov 13, 2026 Peers: Industry group

Head to Head

11 decided of 12

Thermo Fisher Scientific leads on 5 of the 12 questions below (Thermo Fisher Scientific 5, Bio-Rad Laboratories 3, Teva Pharmaceutical Industries 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBIOTEVATMOLeader
Larger companyMarket capitalisation $9.63B $50.87B $254.53B TMO
Cheaper on earningsLower P/E, profitable companies only 9.4x 100.5x 36.0x BIO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 36.0x 22.7x 27.0x TEVA
Faster revenue growthRevenue growth, trailing twelve months +1.4% +2.7% +8.3% TMO
More profitableNet margin, trailing twelve months 39.5% 2.9% 14.9% BIO
Better return on capitalReturn on invested capital -0.6% 5.9% 8.0% TMO
Less leveragedLower net debt / EBITDA — 5.2x 3.1x TMO
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +15.5% +74.4% +20.7% TEVA
Better 5-year returnAnnualised price return, 5 years -13.5%/yr +36.2%/yr +2.0%/yr TEVA
Less volatileAnnualised volatility, 1 year 36.5% 33.4% 30.7% TMO
Higher overall scoreMean of the five percentile scores vs peers 70/100 62/100 60/100 BIO

Percentile Scorecard

BIOTEVATMO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBIOTEVATMO
Valuation 85 #38 of 243 82 #120 of 660 62 #94 of 243
Growth 48 #120 of 228 68 #201 of 619 41 #136 of 228
Profitability 70 #67 of 222 86 #87 of 595 82 #40 of 222
Financial Health 66 #85 of 248 11 #608 of 683 31 #172 of 248
Shareholder Returns 80 #32 of 158 – 82 #29 of 158
Overall 70 62 60
  • BIO ranked among 252 companies in Medical Devices and Diagnostics
  • TEVA ranked among 695 companies in Pharmaceuticals and Biotechnology
  • TMO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBIOTEVATMOSPY
1 month +1.0%+9.3%+4.0% -2.0%
3 months +2.8%+21.1%+19.1% -2.8%
6 months +47.9%+29.9%+59.7% +2.0%
Year to date +20.8%+42.7%+20.8% +10.6%
1 year +15.5%+74.4%+20.7% +12.2%
3 years +19.1%+399.9%+52.5% +68.1%
3 years, per year +6.0%+71.0%+15.1% +18.9%
5 years -51.6%+368.3%+10.2% +61.4%
5 years, per year -13.5%+36.2%+2.0% +10.1%
10 years +119.6%+9.6%+362.9% +248.5%
10 years, per year +8.2%+0.9%+16.6% +13.3%

Risk

MeasureBIOTEVATMOSPY
Volatility, 1Y 36.5%33.4%30.7% 13.6%
Downside volatility, 1Y 35.6%27.5%29.2% 13.9%
Beta vs S&P 500, 1Y 0.750.590.71 1.00
Return / volatility, 1Y 0.432.230.67 0.90
Max drawdown, 5Y -72.2%-43.7%-41.5% -25.4%
From 52-week high -6.2%0.0%-3.0% -3.2%
52-week high $390.34$44.54$721.63 $779.14
52-week low $241.71$24.21$438.34 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBIOTEVATMO
P/E now vs peer median 9.6xmedian 26.5x 102.6xmedian 17.0x 36.6xmedian 26.5x
P/S now vs peer median 3.8xmedian 2.7x 3.0xmedian 8.4x 5.5xmedian 2.7x
EV/EBITDA now vs peer median —median 18.4x 26.7xmedian 14.6x 25.5xmedian 18.4x
P/FCF now vs peer median 29.9xmedian 25.4x 42.0xmedian 19.0x 34.2xmedian 25.4x
P/B now vs peer median 1.3xmedian 2.5x 6.5xmedian 2.0x 4.7xmedian 2.5x
PEG now vs peer median 0.09median 0.98 3.39median 0.43 4.84median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBIOTEVATMO
Revenue $2.59B $17.23B $47.35B
Gross profit $1.33B $9.22B $19.45B
Operating income -$61.90M $1.44B $8.47B
Net income $1.02B $508.00M $7.09B
Free cash flow $329.10M $1.24B $7.60B
R&D $265.80M $1.76B $1.40B
EPS (diluted) $37.96 $0.43 $19.06
Cash & equivalents $465.30M $4.09B $5.46B
Total debt $1.20B $16.72B $41.37B
Shares (diluted) 26.95M 1.18B 371.00M
Enterprise value $3.24B $35.84B $231.04B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBIOTEVATMO
P/E 9.6x 102.6x 36.6x
P/FCF 29.9x 42.0x 34.2x
P/Operating cash flow 21.0x 29.4x 27.8x
P/S 3.8x 3.0x 5.5x
P/B 1.3x 6.5x 4.7x
P/Tangible book 1.3x 11.1x 7.1x
EV/EBITDA – 26.7x 25.5x
EV/EBIT -151.6x 45.0x 34.8x
EV/Revenue 3.6x 3.7x 6.2x
EV/FCF 28.5x 52.3x 38.8x
EV/Operating cash flow 20.1x 36.5x 31.6x
PEG (3Y EPS CAGR) 0.09 3.39 4.84

Growth

14 metrics
MetricBIOTEVATMO
Revenue growth (1Y) 1.4% 2.7% 8.3%
Revenue CAGR (3Y) -1.6% 4.1% 2.9%
Gross profit growth (1Y) -0.6% 9.7% 7.8%
Gross profit CAGR (3Y) -3.0% 9.6% 4.0%
Operating income growth (1Y) -127.6% -21.5% 12.8%
Operating income CAGR (3Y) -29.5% 46.4% 7.2%
Net income growth (1Y) 251.3% -23.3% 7.9%
Net income CAGR (3Y) 103.5% 30.3% 6.2%
EPS growth (1Y) 251.2% -30.1% 9.7%
EPS CAGR (3Y) 107.7% 30.2% 7.6%
Operating cash flow growth (1Y) -4.8% 66.0% 21.9%
Operating cash flow CAGR (3Y) 7.8% 15.2% 4.5%
Free cash flow growth (1Y) -2.3% 113.8% 24.3%
Free cash flow CAGR (3Y) 13.6% 26.7% 5.1%

Profitability

14 metrics
MetricBIOTEVATMO
Gross margin 51.3% 53.5% 41.1%
EBITDA margin – 14.0% 24.4%
Operating margin -2.4% 8.3% 17.9%
Pretax margin 50.9% 2.1% 16.7%
Net margin 39.5% 2.9% 14.9%
FCF margin 12.7% 7.2% 16.0%
Operating cash flow margin 18.1% 10.3% 19.7%
Return on equity 13.8% 6.5% 13.2%
Return on assets 9.7% 1.3% 6.2%
Return on invested capital -0.6% 5.9% 8.0%
Return on capital employed -0.6% 5.9% 8.5%
Asset turnover 0.2x 0.4x 0.4x
Cash conversion (OCF / net income) 0.5x 3.5x 1.3x
Stock comp / revenue 2.4% 1.0% 0.7%

Financial Health

11 metrics
MetricBIOTEVATMO
Debt / assets 11.2% 41.8% 36.2%
Debt / equity 0.2x 2.1x 0.8x
Net debt / EBITDA – 5.2x 3.1x
Debt / FCF 3.7x 13.5x 5.4x
Liabilities / assets 29.5% 80.1% 52.1%
Equity / assets 70.5% 19.9% 47.9%
Interest coverage -1.3x – 12.0x
Current ratio 3.2x 0.9x 1.8x
Quick ratio 2.2x 0.5x 1.2x
Cash ratio 1.7x 0.3x 0.4x
Altman Z-score 3.41 1.02 4.18

Shareholder Returns

7 metrics
MetricBIOTEVATMO
Dividend yield – – 0.3%
Net buyback yield 0.7% – 1.6%
Shareholder yield 0.7% 0.0% 1.8%
Payout ratio (earnings) – – 9.5%
Payout ratio (FCF) – – 8.9%
Dividend growth (1Y) – – 8.0%
Dividend CAGR (3Y) – – 10.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBIOTEVATMO
Forward P/E 36.0xFY2026 22.7xFY2026 27.0xFY2026
EPS, next fiscal year $10.18FY2026 $1.96FY2026 $25.92FY2026
EPS growth, next FY +2.6%FY2026 -33.1%FY2026 +13.3%FY2026
EPS growth, the year after -0.2% +65.3% +2.2%
Revenue, next fiscal year $2.69BFY2026 $15.89BFY2026 $50.12BFY2026
Revenue growth, next FY +4.2%FY2026 -8.0%FY2026 +12.5%FY2026
Revenue growth, the year after -7.4% +16.5% -2.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBIOTEVATMO
Held by institutions 89.5% 62.7% 90.2%
Institutions holding 405 672 2,627
Change in shares held, QoQ -2.9% +8.6% +0.8%
Institutions buying 177 359 1,145
Institutions selling 157 192 1,145
Buyers to sellers 1.13 1.87 1.00

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BIOTEVATMO
BIO 1.00 0.14 0.59
TEVA 0.14 1.00 0.26
TMO 0.59 0.26 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BIO, TEVA and TMO?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Bio-Rad Laboratories (BIO) $9.63B, Teva Pharmaceutical Industries (TEVA) $50.87B, Thermo Fisher Scientific (TMO) $254.53B.

Which stock is cheaper, BIO, TEVA and TMO?

Bio-Rad Laboratories (BIO) trades on the lowest price-to-earnings ratio (Bio-Rad Laboratories (BIO) 9.4x, Teva Pharmaceutical Industries (TEVA) 100.5x, Thermo Fisher Scientific (TMO) 36.0x). On next year's consensus earnings, Teva Pharmaceutical Industries (TEVA) is cheapest (Bio-Rad Laboratories (BIO) 36.0x, Teva Pharmaceutical Industries (TEVA) 22.7x, Thermo Fisher Scientific (TMO) 27.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Bio-Rad Laboratories (BIO) +1.4%, Teva Pharmaceutical Industries (TEVA) +2.7%, Thermo Fisher Scientific (TMO) +8.3%.

Which company is more profitable?

Bio-Rad Laboratories (BIO) has the highest net margin (Bio-Rad Laboratories (BIO) 39.5%, Teva Pharmaceutical Industries (TEVA) 2.9%, Thermo Fisher Scientific (TMO) 14.9%). On return on invested capital, Thermo Fisher Scientific (TMO) leads (Bio-Rad Laboratories (BIO) -0.6%, Teva Pharmaceutical Industries (TEVA) 5.9%, Thermo Fisher Scientific (TMO) 8.0%).

Which stock has performed better?

Over the past year Teva Pharmaceutical Industries (TEVA) returned the most: Bio-Rad Laboratories (BIO) +15.5%, Teva Pharmaceutical Industries (TEVA) +74.4%, Thermo Fisher Scientific (TMO) +20.7%. Over five years, Teva Pharmaceutical Industries (TEVA) compounded fastest (Bio-Rad Laboratories (BIO) -13.5%/yr, Teva Pharmaceutical Industries (TEVA) +36.2%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Bio-Rad Laboratories (BIO) 0.00%, Teva Pharmaceutical Industries (TEVA) 0.00%, Thermo Fisher Scientific (TMO) 0.00%. Bio-Rad Laboratories (BIO) and Teva Pharmaceutical Industries (TEVA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Bio-Rad Laboratories (BIO) 36.5%, Teva Pharmaceutical Industries (TEVA) 33.4%, Thermo Fisher Scientific (TMO) 30.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BIO, TEVA and TMO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.